ASH 2005

Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

Sandra Horning
Sandra Horning

Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.




Click here for all the interviews from ASH 2005

Similar Interviews

  • Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma
  • Owen O'Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O'Connor also gave data from early, two studies: one looking at

  • Audio Journal of Hematologic Malignancy Special Edition 2005
  • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions,

  • Audio Journal of Hematologic Malignancy, Volume 2 Number 1
  • Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10, 2002 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Anton Hagenbeek, University of Utrecht John Goldman,

    Post a comment

    Subscribe to Audio Medica Podcast